Table 2.
Combination therapy with anti-CD137 mAb in mice
| Combination | Materials | Tumor cell | Cell type | Reference |
|---|---|---|---|---|
| Combination with mAb therapy targeting to immune cell | ||||
| Anti–CTLA-4 mAb | 4F10 | MC38 cell | Murine colon cancer cell | (43) |
| Anti-CD40 mAb | FGK-45 | MC38 cell Eμ-Myc cell |
Murine colon cancer cell Murine lymphoma |
(44) |
| Anti-DR5, CD40 mAbs—termed trimAb therapy | MD5-1, FGK45 | 4T1 cell | Murine mammary carcinoma | (45) |
| Anti-DR5, CD40, CTLA-4 mAbs—termed trimAb therapy + anti–CTLA-4 mAb | MD5-1, FGK45, UC10-4F10 | 4T1 cell | Murine mammary carcinoma | (46) |
| Anti-DR5, CD1d mAbs—termed 1DMab | MD5-1, 1B1 | 4T1 cell | Murine mammary carcinoma | (47) |
| Anti–TIM-3 mAb | RMT3-23 | ID8 cell | Murine ovarian carcinoma | (28) |
| Anti-OX40 mAb | MRC OX86 | MethA cell | Murine sarcoma | (48) |
| Anti–PD-1 mAb | RMP1-14 | ID8 cell | Murine ovarian carcinoma | (49) |
| Anti–PD-1, anti–CTLA-4 mAbs | RMP1-14 + 9D9 | TC1 cell | Murine lung epithelial cell | |
| Anti–PD-1 mAb + platinum agent | RMP1-14 + cisplatin | |||
| Anti–PD-1 mAb | RMP1-14 | B16.F10 cell | Murine melanoma cell | (50) |
| Anti–PD-1 mAb | RMP1-14 | CT26 cell | Murine colon adenocarcinoma cells | (51) |
| Combination with vaccination | ||||
| DC vaccine | Tumor lysate–pulsed DCs | MCA205 cell | Murine fibrosarcomas | (33) |
| DC vaccine | Tumor lysate–pulsed DCs | CT26 cell | Murine metastatic colon cancer cell | (52) |
| DC vaccine and anti-OX40 mAb | Tumor lysate–pulsed DCs, OX86 | N202.1A cell | Murine mammary cell line | (53) |
| Adoptive CTL therapy | Tumor-specific CTL | B16.F10 cell | Murine melanoma cell | (69) |
| B16-Flt3L vaccine and anti–CTLA-4 mAb | B16-Flt3 ligand, 9D9 | B16-sFlt3L cell | Murine melanoma cells | (27) |
| CpG vaccine | CpG1826 | Renca cell MC38 cell |
Murine renal cell carcinoma Murine colon tumor cell |
(54) |
| Peptide and CpG vaccine | Trp2 peptides plus CpG | B16 BL6 | Murine melanoma | (55) |
| Oncolytic virus | Oncolytic Vvdd vaccinia virus | AT-3 cell | Murine breast carcinoma | (56) |
| IL12 gene therapy | Adenovirus expressing IL12 | B16.F10 cell | Murine melanoma cell | (70) |
| Virus vaccine and anti–CTLA-4 mAb | Adenovirus with LCMV gene, 9H10 | B16.F10-GP cell | Murine melanoma cell | (57) |
| Combination with mAb therapy targeting to tumor antigen | ||||
| Anti-CD20 mAb | Rituximab | Raji cell | Human CD20+ B cell | (39) |
| Anti-CD20 mAb | MB20-11 | BL3750 cell | Murine CD20+ B cell | |
| Anti-HER2 mAb | Trastuzumab | BT474M1, MCF7 HER18 cells |
Human breast tumor cell | (40) |
| Anti-ErbB-2 mAb and anti–PD-1 mAb | 7.16.4, RMP1-14 | H2N113 cell | Murine ErbB-2+ tumor cell | (59) |
| Anti-EGFR mAb | Cetuximab | SCC6, T84, HCT116 | Human colon cancer cell | (41) |
Abbreviations: CCL2, C–C motif chemokine 2; Trp2, tyrosinase-related protein 2.